The way I understand it Xoma and Novartis will be releasing Phase I data for HCD122 during a oncology get together Dec 5th. This is probably the next news we can look forward to.
Just came across this clinical trial starting for HCD122. Looks like they are beginning another Phase I, this time for Leukemia.
I dont think anything new is really going to be coming out. Most of the links everyone has provided show that phase I is goin well...what more can they possibly say that would be meaningful? I dont think this is the news they were talking about at the CC.
Don't forget HCD122, it will be presented at Dec-5-2007 conference. We may get some great news at Nov-27-2007 presentation (http://biz.yahoo.com/pz/071115/131493.html).
Nasdaq 52 week range 2,331.57 - 2,861.51, now we are at 2,545. Already down over 315 points = 12%!!!
Novartis and Xoma are feeling good about HCD122 with the 3rd indication starting(leukemia). They are escalating the doses and the patient populations. Interesting that Novartis lists HCD122 as planned marketing for 2011 on their website.
HCD122 is a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. This antibody has a dual mechanism of action blocking a tumor cell growth and survival signal, as well as recruiting immune effector cells to kill tumor cells.
HCD122 is the product candidate selected under the multi-product antibody development and commercialization agreement for the treatment of cancer announced by Novartis and the Company.
In addition, there are a number of undisclosed preclinical stage programs that the Company is investigating with Novartis.